Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

  • Katherine A. Lyseng-WilliamsonEmail author
Open Access

1 Correction to: Clinical Drug Investigation (2019) 39:805–819

The original version of this article unfortunately contained some mistakes. The corrected details are provided below:

Page 806, column 1, line 3: The text, which previously read:

‘as and’

should read:


Page 809, Table 2, column 6, row 29: the cell, which was previously blank, should read:


Page 811, column 1, paragraph 2, sentence 4: The two sets of bracketed text, which previously read:

‘(once-weekly dulaglutide, liraglutide and exenatide ER)’ and ‘(twice-daily exenatide and lixisenatide)’

should read:

‘(once-daily liraglutide, once-weekly dulaglutide and once-weekly exenatide ER)’ and ‘(twice-daily exenatide and once-daily lixisenatide)’

Page 812, Table 3, column 3 and Page 814, Table 4, column 5: The column headings, which previously read:

‘Exenatide 20 mg/wk’

Should read:

‘Exenatide 2 mg/wk’

Page 814, Table 4, column 4: The heading, which previously read:

‘Dulaglutide 0.5/1.0 mg/wk’

Should read:

‘Dulaglutide 1.5 mg/wk’

Page 814, Table 4, column 5, row 7: The 95% CI, which previously read:


Should read:


Page 815, Table 5, footnote ‘b’, which previously read:

Exenatide IR and liraglutide are short-acting; lixisenatide, dulaglutide, exenatide ER and semaglutide are long-acting

Should read:

Exenatide IR and lixisenatide are short-acting; dulaglutide, exenatide ER, liraglutide and semaglutide are long-acting.

Copyright information

© Springer Nature 2020

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations